Actinium Pharmaceuticals (ATNM) Q1 2025 earnings summary

Executive summary

• Actinium Pharmaceuticals is advancing targeted radiotherapies for advanced cancers, focusing on myeloid malignancies, solid tumors, and conditioning for cell and gene therapies, with a pipeline including Actimab-A, Iomab-ACT, ATNM-400, and Iomab-B.

• The company initiated new clinical programs in 2025, including Actimab-A in solid tumors and ATNM-400 for prostate cancer, and is seeking partners for further Iomab-B development after FDA feedback.

• Workforce optimization in Q2 2025 reduced headcount by 14%, expected to save $1.15 million in personnel expenses for the remainder of the year.

Financial highlights

• Net loss for Q1 2025 was $15.9 million, up from $8.7 million in Q1 2024, primarily due to higher non-cash stock compensation expense and increased R&D and G&A costs.

• Operating expenses rose to $16.6 million in Q1 2025 from $9.6 million in Q1 2024, with R&D at $7.7 million and G&A at $8.9 million.

• Cash and cash equivalents were $65.3 million as of March 31, 2025, down from $72.9 million at year-end 2024.

• No commercial or grant revenue was recognized in Q1 2025 or Q1 2024; $35 million in deferred license revenue remains from the Immedica agreement, pending EU regulatory approval of Iomab-B.

• No shares were sold in Q1 2025; in Q1 2024, 1.8 million shares were sold for net proceeds of $14.7 million.

Outlook and guidance

• Management expects existing resources to fund planned operations for more than 12 months from the report date.

• Initial clinical data from new Actimab-A and Iomab-ACT trials are expected in the second half of 2025.

• The company is actively seeking strategic partners for Iomab-B to meet FDA requirements for additional clinical trials.